Table 4.
Safety data comparing bevacizumab/pemetrexed vs. bevacizumab alone as maintenance therapy. AVAPERL1 Trial.
| Bevacizumab maintenance (N = 110) |
Bevacizumab/pemetrexed maintenance (N = 117) |
|
|---|---|---|
| Number of AE any grade | 867 | 1134 |
| Number and (%) of patients with AE | 102 (93%) | 110 (94%) |
| Number of AE grade ≥3 | 55 | 44 |
| Number and (%) of patients with grade ≥3 AE | 38 (35%) | 45 (38%) |
| % of patients with AE by phase | ||
| First line | 82 | 86 |
| Maintenance | 65 | 72 |
| % of patients with AE by intensity | ||
| Grade 1/2 | 85/73 | 90/74 |
| Grade 3/4 | 31/4 | 37/6 |
| Grade 5 | 3 | 2 |